Accelerate Your Product to Market with Needle-free Delivery

With PharmaJet’s commercialized products and our technical and clinical expertise, you can progress rapidly from pre-clinical data into successful phase 1, 2 and 3 studies.

60+
Development Partners

 

85+
Studies in Progress

 

45+
Studies Completed

Strategic Alliances with PharmaJet

Many leading pharmaceutical, biotechnology, and academic institutions have formed strategic alliances with PharmaJet to use our needle-free injection systems to enhance the delivery of their injected medicines and vaccines.

Needle-free delivery provides a safe and often, more effective alternative to traditional injection techniques. We have needle-free devices for intradermal (ID), subcutaneous (SC), and intramuscular (IM) delivery in 0.5 ml and 0.1 mL dose volumes. Variable dose devices are in late stages of development.

Click on image to enlarge

Our Needle-free Injection Systems Effectively Deliver

✓ Low and high viscosity medicines

✓ Proteins and peptides

✓ Specialty drug therapies

✓ Nucleic acid-based vaccines and therapeutics

Ongoing Pre-Clinical Studies and Clinical Trials

Infectious Disease

COVID-19

Pre-Clinical Studies

DNA (12)
RNA (2)
Multiple (1)

Phase 1 Clinical Studies

DNA (6)

  • BioNet Asia COVIGEN
  • DIOSynVax
  • Scancell COVIDITY

RNA (1)

Phase 2 Clinical Studies

DNA (1)

  • Nykode VB D-01

Phase 3 Clinical Studies

DNA (1)

  • Zydus Cadila ZyCoV-D
INFLUENZA

Pre-Clinical Studies

DNA (4)
Nanoparticle (1)

  • Influenza
  • Pandemic Influenza
  • Swine Influenza

Phase 1 Clinical Studies

DNA (1)

  • NIH VRC 316 (Influenza)

Phase 2 Clinical Studies

Phase 3 Clinical Studies

HIV/SIV

Pre-Clinical Studies

DNA (3)

  • HIV
  • SIV

Phase 1 Clinical Studies

DNA (3)

  • INSERM/EuroVacc (HIV)
  • Henry M. Jackson Foundation for the Advancement of Military Medicine

Phase 2 Clinical Studies

Phase 3 Clinical Studies

ARBOVIRUSES

Pre-Clinical Studies

DNA (4)

  • Crimean Congo
  • Hemhorragic Fever
  • VEEV
  • Yellow fever
  • Zika

Phase 1 Clinical Studies

Phase 2 Clinical Studies

DNA (1)

  • NIH VRC 705 (Zika)

Phase 3 Clinical Studies

HANTAVIRUSES

Pre-Clinical Studies

DNA (1)

  • Hantaviruses

Phase 1 Clinical Studies

DNA (1)

  • USAMRIID CCHMC (Andes Virus)

Phase 2 Clinical Studies

DNA (1)

  • USAMRIID WRAIR (Hantaan/Puumala)

Phase 3 Clinical Studies

OTHER VIRUSES

Pre-Clinical Studies

DNA (3)
RNA (1)

  • Hepatitis B
  • Marburg Virus
  • PRRSV
  • Smallpox

Phase 1 Clinical Studies

Phase 2 Clinical Studies

Phase 3 Clinical Studies

Therapeutics

CANCER

Pre-Clinical Studies

DNA (3)

  • Canine Cancer
  • Multiple Cancers

Phase 1 Clinical Studies

DNA (5)

  • Duke University (Breast Cancer)
  • Invectys (Therapeutic Cancer)
  • MD Anderson (Lymphoma)

Phase 2 Clinical Studies

DNA (5)

  • Evaxion EVX-02-001 (Melanoma)
  • Invectys (Leukemia)
  • Nykode VB C-02 (HPV)
  • Nykode VB N-01 (Neoantigen)
  • Nykode VB N-02 (Neoantigen)

RNA (1)

  • Ludwig/CureVac/BI (Lung Cancer)

Phase 3 Clinical Studies

AUTOIMMUNE

Pre-Clinical Studies

DNA (1)

  • Alzheimers

Phase 1 Clinical Studies

DNA (2)

  • Alzheimers
  • Vitiligo

Phase 2 Clinical Studies

Phase 3 Clinical Studies

Other Applications

VARIOUS INDICATIONS

Pre-Clinical Studies

DNA Platform (multiple)

mRNA Vaccines (multiple)

Other Injectables (multiple)

Phase 1 Clinical Studies

Subunit (1)

  • Bleeding disorders

Phase 2 Clinical Studies

Phase 3 Clinical Studies

PharmaJet Vaccine Partnerships

We are interested in collaboration opportunities with partners where our technology can enhance the delivery of injectables in areas such as biologics, vaccines, small molecules, and other therapeutic technology platforms.

PharmaJet currently has active collaborations with a wide variety of partners including emerging biotechnology companies, established pharmaceutical companies, Armed Forces/DoD (Department of Defense), Federal Agencies, among others.

Menu